- DONE [#A] PREGUNTAR a [[Marina]] y [[Silvia]] si tienen claras algunas de las invitaciones que podríamos ir mandando ya para que [[yo]] vaya preparándolo
- [[AK]]. To begin with ty to them. To be part of the STAB meeting and being availsable at the same time. I prepared a presentation which wont take more than 20-25 mins an get your input. We really value this. Adhoc afiliation with Liconsa. Affiliation to FMS. Estuvo en previous stop durante el ALIVE study.
- John Amuasi: physician. Global health infectious diseases and global health department.
- Denise Mupfasoni: NTD department at WHO leading all the STH related activities. Key stakeholder on our. Geneva. Member as an observer in this group. Not a full member.
- WP3 leaded by KEMRI: leaded by modelling and db but also as a siste.
- wp4: the social sciences: acceptabiility feasibility and adherence: also clinical site, but also a leader through their expertise on other projects on acceptaibility.
- We know that the FDC también es util para oncho, lf, scabies y demás pero tenemos que elegir una disease of particular interest to perform the particular studies. So far the achievements have been: submission to EMA through art 58. the main target is leading the way to prequalification to WHO. We did the pivotal trial that demonstrated safety efficacy against T. Trichiura.
- We look for your expertise in these 3 aspects. Our interest is go beyond the science limited to STH and a vision of global health and a program of implementation.
- Generate the evidence and arguments to our policy and access planning communicating with the correct stakehoulders and provide us input and give visibility to the project.
